Apoptosis induced by selenomethionine and methioninase is superoxide mediated and p53 dependent in human prostate cancer cells

Molecular Cancer Therapeutics

Volumn 5, Issue 12, 2006, Pages 3275-3284

  Zhao, Rui ^a   Domann, Frederick E ^c   Zhong, Weixiong ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYTOCHROME C; MANGANESE TETRAKIS(N METHYL 2 PYRIDYL)PORPHYRIN; METHIONINE GAMMA LYASE; PORPHYRIN DERIVATIVE; PROTEIN BAX; PROTEIN P53; SELENIUM; SELENOMETHIONINE; SUPEROXIDE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER PREVENTION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOSOL; DRUG POTENTIATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MALE; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN TRANSPORT; RNA INTERFERENCE; WILD TYPE;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CARBON-SULFUR LYASES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; MITOCHONDRIA; PROSTATIC NEOPLASMS; SELENOMETHIONINE; SUPEROXIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33846229626     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0400     Document Type: Article

References (51)

1. Combs GF, Jr., Gray WP. Chemopreventive agents: selenium. Pharmacol Ther 1998;79:179-92.
2. Ip C. Lessons from basic research in selenium and cancer prevention. J Nutr 1998;128:1845-54.
3. Clark LC, Combs GF, Jr., Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996;276:1957-63.
4. Clark LC, Dalkin B, Krongrad A, et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br J Urol 1998;81:730- 4.
5. Sinha R, El-Bayoumy K. Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy by selenium compounds. Curr Cancer Drug Targets 2004;4:13-28.
6. Combs GF. Status of selenium in prostate cancer prevention. Br J Cancer 2004;91:195-9.
7. Zhong W, Oberley TD. Redox-mediated effects of selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line. Cancer Res 2002;61:7071-8.
8. Zhao R, Xiang N, Domann FE, et al. Expression of p53 enhances selenite-induced superoxide production and apoptosis in human prostate cancer cells. Cancer Res 2006;66:2296-304.
9. Wei Y, Cao X, Qu Y, et al. SeO(2) induces apoptosis with down-regulation of Bcl-2 and up-regulation of p53 expression in both immortal human hepatic cell line and hepatoma cell line. Mut Res 2001;490: 113-21.
10. Jiang C, Hu H, Malewicz B, et al. Selenite-induced p53 Ser-15 phosphorylation and caspase-mediated apoptosis in LNCaP human prostate cancer cells. Mol Cancer Ther 2004;3:877-84.
11. Seo YR, Kelley MR, Smith ML. Selenomethionine regulation of p53 by a ref1-dependent redox mechanism. Proc Natl Acad Sci U S A 2002;99: 14548-53.
12. Lanfear J, Fleming J, Wu L, et al. The selenium metabolite selenodiglutathione induces p53 and apoptosis: relevance to the chemopreventive effects of selenium? Carcinogenesis 1994;15:1387-92.
13. Ip C, Ganther HE. Relationship between the chemical forms of selenium and anticarcinogenic activity. In: Wattenberg L, Lipkin M, Boone CW, Kelloff GJ, editors. Cancer chemoprevention. Boca Raton (FL): CRC Press; 1992. p. 479-88.
14. Spallholz JE. On the nature of selenium toxicity and carcinostatic activity. Free Radic Biol Mad 1994; 17:45-64.
15. Ip C, Hayes C, Budnick RM, Ganther HE. Chemical form of selenium, critical metabolites, and cancer prevention. Cancer Res 1991;51:595-600.
16. Rizky A, Kaori Mi, Minato N, et al. Chemical forms of selenium for cancer prevention. J Trace Elem Med Biol 2005;19:141-50.
17. 2 cells. Int J Cancer 1999; 81:820-8.
18. Jung U, Zheng X, Yoon SO, Chung AS. Se-methylselenocysteine induces apoptosis mediated by reactive oxygen species in HL-60 cells. Free Radic Biol Med 2001;31:479-89.
19. Kim TS, Yun BY, Kim Y. Induction of the mitochondrial permeability transition by selenium compounds mediated by oxidation of the protein thiol groups and generation of the superoxide. Biochem Pharmacol 2003; 66:2301-11.
20. Miki K, Xu M, Gupta A, et al. Methioninase cancer gene therapy with selenomethionine as suicide prodrug substrate. Cancer Res 2001;61: 6805-10.
21. Miki K, Al-Refaie W, Xu M, et al. Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment. Cancer Res 2000;60:2696-702.
22. Gupta A, Miki K, Xu M, et al. Combination efficacy of doxorubicin and adenoviral methioninase gene therapy with prodrug selenomethionine. Anticancer Res 2003;23:1181-8.
23. Yamamoto N, Gupta A, Xu M, et al. Methioninase gene therapy with selenomethionine induces apoptosis in bcl-2-overproducing lung cancer cells. Cancer Gene Ther 2003;10:445-50.
24. 1 arrest by selenium metabolite methylselenol. Mol Carcinog 2002;34:113-20.
25. Spallholz JE, Palace VP, Reid TW. Methioninase and selenomethionine but not Se-methylselenocysteine generate methylselenol and super-oxide in an in vitro chemiluminescent assay: implications for the nutritional carcinostatic activity of selenoamino acids. Biochem Pharmacol 2004;67:547-54.
26. Peters TR, Tosk JM, Goulbourne EA, Jr. Lucigenin chemiluminescence as a probe for measuring reactive oxygen species production in Escherichia coli. Anal Biochem 1990;186:316-9.
27. Rogakou EP, Pilch DR, Orr AH, et al. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998; 273:5858-68.
28. Macip S, Igarashi M, Berggren P, Yu J, Lee SW, Aaronson SA. Influence of induced reactive oxygen species in p53-mediated cell fate decisions. Mol Cell Biol 2003;23:8576-85.
29. Hofseth LJ, Hussain SP, Harris CC. p53: 25 years after its discovery. Trends Pharmacol Sci 2004;25:177-81.
30. Johnson TM, Yu ZX, Ferrans VJ, et al. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc Natl Acad Sci U S A 1996;93:11848-52.
31. Marchenko ND, Zaika A, Moll LIM. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 2000;275:16202-12.
32. Polyak K, Xia Y, Zweier JL, et al. A model for p53-induced apoptosis. Nature 1997;389:300-5.
33. Chaudiere J, Courtin O, Leclaire J. Glutathione oxidase activity of selenocystamine: a mechanistic study. Arch Biochem Biophys 1992;296: 328-36.
34. Zhong W, Yan T, Webber MM, at al. Alteration of cellular phenotype and responses to oxidative stress by manganese superoxide dismutase and a superoxide dismutase mimic in RWPE-2 human prostate adenocarcinoma cells. Antioxid Redox Signal 2004;6:513-22.
35. Menter DG, Sabichi AL, Lippman SM. Selenium effects on prostate cell growth. Cancer Epidemiol Biomarkers Prev 2000;9:1171-82.
36. Husbeck B, Norm L, Peehl DIM, Knox SJ. Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate 2005;66:218-25.
37. Amanda EM, Thomas E, John W, et al. The primitive protozoon Trichomonas vaginalis contains two methionine γ-lyase genes that encode members of the γ-family of pyridoxal 5′-phosphate-dependent enzymes. J Biol Chem 1998;273:5549-56.
38. Tomofumi O, Tomoyuki K, Tomonori K, et al. Contribution of enzymic α,γ-elimination reaction in detoxification pathway of selenomethionine in mouse liver. Toxicol Appl Pharmacol 2001; 176:18-23.
39. Rooseboom M, Commancleur JN, Vermeulen NP. Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 2004;56:53-102.
40. Rooseboom M, Vermeulen NP, Groot EJ, Commancleur JN. Tissue distribution of cytosolic 3-elimination reactions of selenocysteine Seconjugates in rat and human. Chem Biol Interact 2002;140:243-64.
41. Tomofumi O, Shinji M, Hitoshi U, et al. Purification and characterization of mouse hepatic enzyme that converts selenomethionine to methylselenol by its α,γ-elimination. Biol Trace Elern Res 2005; 106:77-94.
42. Ip C, Thompson HJ, Zhu Z, et al. In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylated selenium metabolite is critical for cancer chemoprevention. Cancer Res 2000;60: 2882-6.
43. Spallholz JE, Shriver BJ, Reid TW. Dimethyldiselenicle and methylseleninic acid generate superoxide in an in vitro chemiluminescence assay in the presence of glutathione: implications for the anticarcinogenic activity of L-selenomethionine and L-Se-methylselenocysteine. Nutr Cancer 2001;40:34-41.
44. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
45. Burns TF, El-Deiry WS. The p53 pathway and apoptosis. J Cell Physiol 1999; 181:231-9.
46. Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today 1997; 18:44-51.
47. Li PF, Dietz R, von Harsdorf R. p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO J 1999; 18:6027-36.
48. Chandel NS, Vander Heiden MG, Thompson CB, et al. Redox regulation of p53 during hypoxia. Oncogene 2000; 19:3840-8.
49. Miyashita T, Reed JC, Tumor suppressor p53 is a direct transcriptional activator of the human Bax gene. Cell 1995;80:293-9.
50. Dong Y, Lee SO, Zhang H, et al. Prostate specific antigen expression is down-regulated by selenium through disruption of androgen receptor signaling. Cancer Res 2004;64:19-22.
51. Husbeck B, Bhattacharyya RS, Feldman D, et al. Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action. Mol Cancer Ther 2006;5:2078-85.